Interestingly, three out of five mice that received 4 × 100 μg TMV vaccine dose (Figure 2D) survived tumor-free, whereas only one survived in each group that had received 2 × 200 μg (Figure 2C) or 1 × 400 μg (Figure 2B) dose level, and anti-PD1 antibody did not show any effect on the mice with established tumors (Figure 2C,D). Here, PDCD1 is linked to neoplasm.